MedTrace Logo

Plasma Exchange for Amanita Toxin-induced Acute Liver Failure

NCT06187220 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2025-03-12

No results posted yet for this study

Summary

Retrospective evaluation of the value of additive therapeutic plasma exchange (PEX) compared to standard medical therapy (SMT) in Amanita toxin-associated acute liver failure in children and adolescents within the last 10 years at a international group of liver transplant centers.

Conditions

  • Acute Liver Failure

Interventions

DEVICE

Therapeutic Plasma Exchange (PEX)

Therapeutic plasma exchange with treatment sessions \>=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Klaus Stahl, MD · Hannover Medical School, Hannover Germany

  • Richard Taubert, MD · Hannover Medical School, Hannover Germany

Eligibility

Min Age
0 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-03-10
Completion
2025-03-10

Countries

  • Germany
  • Italy
  • Mexico
  • Portugal
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06187220 on ClinicalTrials.gov